Cisplatin: Clinical Trials

701 trials of Cisplatin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

372 completed, 102 terminated, 76 recruiting, 51 unknown. 701 Phase 1, 266 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1701Completed 372, Terminated 102, Recruiting 76, Unknown 51, Withdrawn 43, Active not recruiting 39, Not yet recruiting 13, Suspended 3, Enrolling by invitation 2
Phase 2266Completed 112, Terminated 47, Recruiting 37, Unknown 31, Withdrawn 18, Active not recruiting 15, Not yet recruiting 5, Suspended 1

Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin

Trials (filtered) newest first · largest first

All 701 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer
Phase 1SuspendedUniversity of Maryland, Baltimore502027-01-302026-09-14
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1Not yet recruitingInSilico Medicine Hong Kong Limited1592026-12-302026-07-23
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Phase 1Not yet recruitingNational Cancer Institute (NCI)162026-12-302026-11-06
Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies
Liposomal Irinotecan Plus Cisplatin - Advanced Solid Malignancies
Phase 1Not yet recruitingNational Health Research Institutes, Taiwan442026-12-012026-11-02
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)602026-11-252026-11-20
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.842026-11-012026-09-29
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin, Pembrolizumab + Gemcitabine/Cisplatin - Intrahepatic Cholangiocarcinoma (Icc)
Phase 1 / Phase 2Not yet recruitingShanghai 6th People's Hospital1122026-09-152026-08-28
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
DXC006, Toripalimab, Carboplatin - Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingHangzhou DAC Biotechnology Co., Ltd.2002026-08-192026-09-24
Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer
cisplatin (cis-diamminedichloroplatinum(II) (CDDP)) - Lung Cancer Metastatic, Lung Cancer (NSCLC)
Phase 1Not yet recruitingUniversity of Vermont122026-07-012026-03-27
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
Becotatug Vedotin Combined with Cisplatin and Concurrent Radiotherapy - Esophageal Squamous Cell Carcinoma
Phase 1Not yet recruitingHebei Medical University Fourth Hospital122026-07-012026-07-10
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin - Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
Phase 1Not yet recruitingHaisco Pharmaceutical Group Co., Ltd.2582026-07-012026-07-14
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma
Phase 1RecruitingJonsson Comprehensive Cancer Center462026-05-292026-08-20
QLS5132 Combination Therapy in Advanced Solid Tumors
QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.6262026-04-012026-03-06
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Emavusertib, Gemcitabine, Cisplatin - Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Phase 1RecruitingWashington University School of Medicine482026-03-272026-04-03
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
KRC-01, External Beam Radiation Therapy, cisplatin - Cervical Cancer
Phase 1RecruitingKortuc, Inc.702026-03-012026-04-08
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
Audiometric Test, Cisplatin, Computed Tomography - Hearing Loss, Metastatic Malignant Germ Cell Tumor
Phase 1RecruitingCity of Hope Medical Center442026-02-192026-04-17
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CR-001, Paclitaxel, trifluridine and tipiracil - Locally Advanced / Metastatic Solid Tumors
Phase 1 / Phase 2RecruitingCrescent Biopharma, Inc.5402026-02-172026-11-13
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
7MW3711, JS207, Cisplatin - Solid Tumor
Phase 1 / Phase 2RecruitingMabwell (Shanghai) Bioscience Co., Ltd.2802026-02-112026-03-12
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg - Advanced Biliary Tract Carcinoma
Phase 1 / Phase 2RecruitingTongji Hospital292026-01-302026-03-23
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1 / Phase 2RecruitingRevolution Medicines, Inc.3702026-01-302026-11-04

Showing 20 of 701. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (123)  ·  Squamous Cell Carcinoma of Head and Neck (71)  ·  Neoplasms (65)  ·  Head and Neck Neoplasms (57)  ·  Lung Neoplasms (54)  ·  Stomach Neoplasms (39)  ·  Uterine Cervical Neoplasms (38)  ·  Neoplasm Metastasis (36)  ·  Ovarian Neoplasms (35)  ·  Small Cell Lung Carcinoma (32)  ·  Colorectal Neoplasms (31)  ·  Pancreatic Neoplasms (31)  ·  Esophageal Neoplasms (28)  ·  Urinary Bladder Neoplasms (26)  ·  Cholangiocarcinoma (25)

Sponsors

National Cancer Institute (NCI) (50)  ·  Memorial Sloan Kettering Cancer Center (31)  ·  Eli Lilly and Company (23)  ·  M.D. Anderson Cancer Center (16)  ·  AstraZeneca (13)  ·  Merck Sharp & Dohme LLC (13)  ·  Pfizer (12)  ·  Dana-Farber Cancer Institute (11)  ·  Gynecologic Oncology Group (10)  ·  City of Hope Medical Center (8)  ·  Hoffmann-La Roche (8)  ·  ImmunityBio, Inc. (8)  ·  Roswell Park Cancer Institute (8)  ·  GlaxoSmithKline (7)  ·  University Health Network, Toronto (7)

Countries

United States (417)  ·  China (101)  ·  Spain (69)  ·  France (63)  ·  South Korea (54)  ·  Canada (53)  ·  Japan (49)  ·  United Kingdom (48)  ·  Italy (36)  ·  Taiwan (35)  ·  Australia (33)  ·  Germany (32)  ·  Belgium (29)  ·  Netherlands (24)  ·  Switzerland (14)

Top investigators

David H. Ilson, MD, PhD (5)  ·  Corey J. Langer, MD (3)  ·  Franco M. Muggia, MD (3)  ·  Gary K. Schwartz, MD (3)

Results publications

PMID 27246305, PMID 32571298, PMID 11181662, PMID 11573045, PMID 12607634, PMID 12717353, PMID 12771884, PMID 12885811, PMID 14666038, PMID 15033677, PMID 15131031, PMID 15328179, PMID 15863167, PMID 15890573, PMID 15958629, PMID 16149148, PMID 16170174, PMID 16368439, PMID 16394300, PMID 16889823, PMID 17084549, PMID 17140960, PMID 17336213, PMID 17398031, PMID 17410043, PMID 17482376, PMID 17538162, PMID 17538163, PMID 18299147, PMID 18628474, PMID 19010522, PMID 19100600, PMID 19139178, PMID 19219674, PMID 19221754, PMID 19228749, PMID 19509178, PMID 19636012, PMID 19738454, PMID 20022092, PMID 20605352, PMID 20818904, PMID 20923544, PMID 21205757, PMID 21220472, PMID 21257722, PMID 21307147, PMID 21412168, PMID 21892091, PMID 22010014

NIH funding

2023 (13), U10CA027469 (12), 2016 (11), 2015 (8), P30CA033572 (8), 2009 (7), 2017 (6), 2018 (6), U10CA180868 (6), P30CA015083 (5), 2008 (4), 2014 (4), 2025 (4), P30CA015704 (4), P30CA043703 (4)